RGRebecca A. Garlena

Rebecca A. Garlena

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rebecca A. Garlena has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Anti-mycobacterial activity of phage-encoded lysterases

    by Jindanuch Maneekul, Krista G. Freeman, Elizabeth D. Amarh, Julia M. Kovalski, Emma Skeel, Manisha Vannan, Matthew T. Montgomery, Casey Moyer, Rebecca A. Garlena, Amit K. Singh, et al.

    Mycobacterium abscessus is a non-tuberculous Mycobacterium (NTM) that is often associated with respiratory infections in persons with cystic fibrosis. High levels of antibiotic resistance make M. abscessus infections difficult to treat, highlighting the urgent need for alternative therapeutic strategies. Mycobacteriophage therapy—treatment of infections with viruses that infect Mycobacterium hosts—shows considerable promise, but the narrow host specificity of the current mycobacteriophage repertoire limits this approach to personalized therapies. Here, we characterize the anti- M . abscessus activity of mycobacteriophage-encoded Lysin B enzymes (lysterases). Lysterases are serine-esterases that cleave the ester bonds linking mycolic acids to either arabinogalactan or trehalose in the mycobacterial cell envelope to complete the lysis process. In this study, we explored their ability to kill a spectrum of clinically isolated M. abscessus strains when administered exogenously. Six phylogenetically distinct lysterases were purified, characterized on the surrogate M. smegmatis , and their activity against a diverse panel of 24 M. abscessus clinical strains was assessed. The enzymes exhibit a range of activities against these strains, but most have broad-spectrum activity with only minor variations among the M. abscessus isolates. However, the activities can be quite potent, resulting in up to six orders of magnitude of reduction in viability within 4 h with one activity unit of the enzymes, and act synergistically with amikacin. Overall, mycobacteriophage-encoded lysterases show considerable potential for antimycobacterial control, especially for topical applications. IMPORTANCE: Mycobacterium infections are clinically challenging, and there is a high failure of resolving Mycobacterium abscessus infections using antibiotics. Mycobacteriophages show promise in treating M. abscessus infections, but there is substantial variation among clinical isolates in their phage infection profiles. Mycobacteriophages are unusual in coding for lysis enzymes—lysterases—that target cell wall exposed constituents, and these can have potential antibacterial activity. Exploring the vast sequence diversity of thousands of phage-encoded lysterases identifies a subset that was expressed, purified, and tested for their ability to kill a broad range of M. abscessus clinical strains. Lysterases with the broadest and greatest activity offer substantial potential for treatment of M. abscessus infection, especially where they display synergism with current antibiotics.

  • Open Access

    Bacteriophage Therapy of Mycobacterium abscessus Mastoiditis

    by Bradford Becken, Michael J Lauer, Daniel A Russell, Rebecca A Garlena, Madison Cristinziano, Lawrence Abad, Rebekah M Dedrick, Deborah Jacobs-Sera, Colin Driscoll, Jennifer Zwiener, et al.

    We describe a case of a child with macrolide-resistant Mycobacterium abscessus who initially had clinical improvement on a dual β-lactam regimen but continued to have positive cultures. Suitable phages active against the bacterial strain were identified, administered both systemically and directly to the ear, and were associated with microbiological remission.

  • Open Access

    Mycobacterium trehalose polyphleates are required for infection by therapeutically useful mycobacteriophages BPs and Muddy

    by Katherine S. Wetzel, Morgane Illouz, Lawrence Abad, Haley G. Aull, Daniel A. Russell, Rebecca A. Garlena, Madison Cristinziano, Silke Malmsheimer, Christian Chalut, Graham F. Hatfull, et al.

    Mycobacteriophages are good model systems for understanding their bacterial hosts and show promise as therapeutic agents for nontuberculous mycobacterium infections. However, little is known about phage recognition of Mycobacterium cell surfaces, or mechanisms of phage resistance. We show here that surface-exposed trehalose polyphleates (TPPs) are required for infection of Mycobacterium abscessus and Mycobacterium smegmatis by clinically useful phages BPs and Muddy, and that TPP loss leads to defects in adsorption, infection, and confers resistance. Transposon mutagenesis indicates that TPP loss is the primary mechanism for phage resistance. Spontaneous phage resistance occurs through TPP loss, and some M. abscessus clinical isolates are phage-insensitive due to TPP absence. Both BPs and Muddy become TPP-independent through single amino acid substitutions in their tail spike proteins, and M. abscessus mutants resistant to TPP-independent phages reveal additional resistance mechanisms. Clinical use of BPs and Muddy TPP-independent mutants should preempt phage resistance caused by TPP loss.